Potential Drug Paves the Way for Biggest Breakthrough in Throat Cancer Treatment

The medication used to treat ovarian cancer was found to stop the growth of tumors in the throat and also increased the effectiveness of chemotherapy.

Ovarian cancer drug showed potential to treat throat cancer when it was subjected to esophageal cancer patients, says a new study.

Researchers from Melbourne's Peter MacCallum Cancer Center used a drug developed in Sweden to treat ovarian cancer and tested it on esophageal cancer patients.

California-Based Company Launches �Liquid Biopsy� to Detect Cancer DNA in Healthy People
Pathway Genomics screening test will look at 96 genetic markers associated with major cancer types such as breast, ovarian, lung, colon and melanoma.

”The medication was found to have stopped the growth of tumors in the throat and also increased the effectiveness of chemotherapy,” according to lead researcher, Professor Wayne Phillips.

Phillips believed the finding was the biggest breakthrough in the treatment of the cancer in three decades.

"The basic treatment that we use for esophageal cancer hasn't changed much over the last 30-odd years. This is a completely new approach that we hope will have good efficacy," said Phillips.

Commonly Used Drugs May Lower Risk For Breast Cancer In Those With Flawed Genes
Gene BRCA1 and its sister BRCA2 are responsible for close to 5,000 cases of breast cancer each year in the UK. The disease tends to strike earlier for these women.

The Australian Cancer Council says esophageal cancer, which is often caused by long-term smoking and alcohol use, affects more than 1,000 Australians each year.

Phillips explained the treatment was not a silver bullet for those with esophageal cancer, with chemotherapy still a crucial part of patients entering remission.

New Innovative Implant Captures Circulating Cancer Cells In Mice
Animals receiving an implant had a significantly reduced burden of disease in their lungs relative to animals that did not have an implant.

"What we've found is that it synergizes with the effects of chemotherapy, so if you add chemotherapy to the tumors, you find a decrease in the tumor growth. If you add the drug by itself, you get a decrease, but if you put the two together, we seem to get more than additive effects in blocking the tumor growth,” he added.

Clinical trials for further use of the drug could likely begin early next year, with the medication added to the existing treatment process.

New Class of Cancer Drugs Developed at Saint Louis University in the US
SR9243 is the new compound, which started as an anti-cholesterol drug candidate. It turns down fat synthesis so that cells can't produce their own fat.

Source-IANS